Transanal TME delivers strong outcomes for rectal cancer

Transanal total mesorectal excision (TATME) shows promising long-term results for patients with low rectal cancer.

Consider TATME for resectable mid and low rectal tumors; ongoing monitoring of long-term outcomes remains essential.

Significant late complications in 32% of patients, with 21 classified as severe (Clavien-Dindo ≥3).
Recurrence linked to preoperative N stage, lymph node yield, tumor deposits, and perineural invasion.

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

More in Intestine and Lower Gastrointestinal Tract

Ann Surg Oncol2 Nov 2026

Patients smoking at diagnosis were less likely to have a favorable response to treatment before rectal cancer surgery; former smokers were not.

JAMA Surg30 Oct 2026

For severe slow-transit constipation, removing less colon gave similar symptom relief at one year, with less early incontinence.

Surg Endosc29 Oct 2026

In low rectal cancer surgery, removing the specimen through the anus was linked to fewer wound complications and less pain in the first two days.